Literature DB >> 6499302

The overall mortality rate in patients with total hip arthroplasty, with special reference to coxarthrosis.

H Lindberg, A S Carlsson, J Lanke, V Horstmann.   

Abstract

The mortality rate was calculated in 1385 patients with total hip arthroplasties compared with the population at risk in the period from 1968 to 1981. In elderly women with coxarthrosis, after the age of 70, the mortality rate decreased after the first postoperative year. There was no such effect in men. In women, there were no changes in mortality rate in those who had had revision operations, whereas in men operated on for coxarthrosis who were over the age of 70, there was an increased mortality rate after the first postoperative year following revision. Patients operated on for complications after hip fracture and/or rheumatoid arthritis had an increased mortality rate after the first postoperative year, including both women and men below age 70.

Entities:  

Mesh:

Year:  1984        PMID: 6499302

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  3 in total

Review 1.  Correlation between patient age at total hip replacement surgery and lifeexpectancy.

Authors:  Carlos Roberto Schwartsmann; Leandro de Freitas Spinelli; Leonardo Carbonera Boschin; Anthony Kerbes Yépez; Marcus Vinicius Crestani; Marcelo Faria Silva
Journal:  Acta Ortop Bras       Date:  2015 Nov-Dec       Impact factor: 0.513

Review 2.  Patient characteristics affecting the prognosis of total hip and knee joint arthroplasty: a systematic review.

Authors:  Pasqualina L Santaguida; Gillian A Hawker; Pamela L Hudak; Richard Glazier; Nizar N Mahomed; Hans J Kreder; Peter C Coyte; James G Wright
Journal:  Can J Surg       Date:  2008-12       Impact factor: 2.089

3.  Long-term Mortality After Revision THA.

Authors:  Jie J Yao; Hilal Maradit Kremers; Matthew P Abdel; Dirk R Larson; Jeanine E Ransom; Daniel J Berry; David G Lewallen
Journal:  Clin Orthop Relat Res       Date:  2018-02       Impact factor: 4.176

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.